{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:42:17Z","timestamp":1788385337646,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016065","name":"Stichting Stofwisselkracht","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare rapidly progressive neurodegenerative disorder, resulting in early death. Intracerebroventricular enzyme replacement therapy (ERT) with cerliponase alfa is now available and has shown to delay disease progression in symptomatic patients. It is yet unknown if cerliponase alfa can prevent disease onset in presymptomatic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We evaluated the effect of 2\u00a0years of intracerebroventricular ERT in two siblings with CLN2 disease, one symptomatic (age 47\u00a0months) and one presymptomatic (age 23\u00a0months) at treatment start, using the CLN2 Clinical Rating Scale (CLN2 CRS), Gross Motor Function Measure-66 (GMFM-66) for motor function, Bayley Scales of Infant and Toddler Development, 3rd Edition, Dutch (BSID-III-NL) for neurocognitive development, brain MRI, and visual evoked potentials (VEP), electroretinogram (ERG) and retinoscopy for visual function. On the CLN2 CRS patient 1 showed a decline from 3 to 2 in the combined motor and language score due to regression in language use (CLN2 CRS total score after 2\u00a0years of treatment: 8), whereas a decline of 2 or more points in the combined motor and language score would be expected without treatment. Patient 2 retained the maximum score of 3 in all 4 subdomains (CLN2 CRS total score after 2\u00a0years of treatment: 12). The GMFM-66 total score declined from 46 to 39 in patient 1 and showed an age-appropriate increase from 66 to 84 in patient 2. Cognitive-developmental age decreased from 24 to 11\u00a0months in patient 1, whereas an increase in cognitive-developmental age from 21 to 39\u00a0months was seen in patient 2. Cerebral and cerebellar atrophy observed on MRI in patient 1 at age 42\u00a0months (before treatment) was not observed in patient 2 at age 48\u00a0months (after 2\u00a0years of treatment).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We show that cerliponase alfa is able to delay the onset of symptoms when treatment is started in a presymptomatic stage of CLN2 disease. Our results advocate the start of treatment at an early age before symptom onset, but should be confirmed in a larger cohort study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01858-6","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T09:02:26Z","timestamp":1620982946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa"],"prefix":"10.1186","volume":"16","author":[{"given":"J.","family":"Schaefers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. J.","family":"van der Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Klees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. H.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sieverdink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H. G.","family":"Dremmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. K. H.","family":"Spoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M. P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-0931","authenticated-orcid":false,"given":"H. H.","family":"Huidekoper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"issue":"5333","key":"1858_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1126\/science.277.5333.1802","volume":"277","author":"DE Sleat","year":"1997","unstructured":"Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, et al. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science. 1997;277(5333):1802\u20135.","journal-title":"Science"},{"issue":"6","key":"1858_CR2","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1086\/302427","volume":"64","author":"DE Sleat","year":"1999","unstructured":"Sleat DE, Gin RM, Sohar I, Wisniewski K, Sklower-Brooks S, Pullarkat RK, et al. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet. 1999;64(6):1511\u201323.","journal-title":"Am J Hum Genet"},{"issue":"1\u20132","key":"1858_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1006\/mgme.2000.3071","volume":"71","author":"J Suopanki","year":"2000","unstructured":"Suopanki J, Partanen S, Ezaki J, Baumann M, Kominami E, Tyynela J. Developmental changes in the expression of neuronal ceroid lipofuscinoses-linked proteins. Mol Genet Metab. 2000;71(1\u20132):190\u20134.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"1858_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2(8):582\u201390.","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"1858_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","volume":"112","author":"R Steinfeld","year":"2002","unstructured":"Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112(4):347\u201354.","journal-title":"Am J Med Genet"},{"issue":"6","key":"1858_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","volume":"69","author":"S Worgall","year":"2007","unstructured":"Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007;69(6):521\u201335.","journal-title":"Neurology"},{"issue":"4","key":"1858_CR7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/dmcn.14346","volume":"62","author":"B Dozieres-Puyravel","year":"2020","unstructured":"Dozieres-Puyravel B, Nasser H, Elmaleh-Berges M, Lopez Hernandez E, Gelot A, Ilea A, et al. Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol. 2020;62(4):528\u201330.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1858_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/humu.21624","volume":"33","author":"M Kousi","year":"2012","unstructured":"Kousi M, Lehesjoki AE, Mole SE. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat. 2012;33(1):42\u201363.","journal-title":"Hum Mutat"},{"issue":"3","key":"1858_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","volume":"74","author":"SJ Moore","year":"2008","unstructured":"Moore SJ, Buckley DJ, MacMillan A, Marshall HD, Steele L, Ray PN, et al. The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland. Clin Genet. 2008;74(3):213\u201322.","journal-title":"Clin Genet"},{"issue":"1\u20132","key":"1858_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jns.2015.05.021","volume":"356","author":"R Di Giacopo","year":"2015","unstructured":"Di Giacopo R, Cianetti L, Caputo V, La Torraca I, Piemonte F, Ciolfi A, et al. Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs. J Neurol Sci. 2015;356(1\u20132):65\u201371.","journal-title":"J Neurol Sci"},{"issue":"11","key":"1858_CR11","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/humu.23860","volume":"40","author":"E Gardner","year":"2019","unstructured":"Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE. Mutation update: review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat. 2019;40(11):1924\u201338.","journal-title":"Hum Mutat"},{"issue":"3","key":"1858_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","volume":"6","author":"SE Mole","year":"2005","unstructured":"Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics. 2005;6(3):107\u201326.","journal-title":"Neurogenetics"},{"key":"1858_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los RE, Denecke J, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102\u201312.","journal-title":"Pediatr Neurol"},{"issue":"11","key":"1858_CR14","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","volume":"1832","author":"A Schulz","year":"2013","unstructured":"Schulz A, Kohlschutter A, Mink J, Simonati A, Williams R. NCL diseases-clinical perspectives. Biochim Biophys Acta. 2013;1832(11):1801\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"20","key":"1858_CR15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los RE, Gissen P, Ballon D, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898\u2013907.","journal-title":"N Engl J Med"},{"issue":"11","key":"1858_CR16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Cerliponase alfa: first global approval. Drugs. 2017;77(11):1247\u20139.","journal-title":"Drugs"},{"issue":"1","key":"1858_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2013.08.008","volume":"50","author":"RH Jadav","year":"2014","unstructured":"Jadav RH, Sinha S, Yasha TC, Aravinda H, Gayathri N, Rao S, et al. Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol. 2014;50(1):85\u201395.","journal-title":"Pediatr Neurol"},{"issue":"8","key":"1858_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/jpc.14890","volume":"56","author":"AM Johnson","year":"2020","unstructured":"Johnson AM, Mandelstam S, Andrews I, Boysen K, Yaplito-Lee J, Fietz M, et al. Neuronal ceroid lipofuscinosis type 2: an Australian case series. J Paediatr Child Health. 2020;56(8):1210\u20138.","journal-title":"J Paediatr Child Health"},{"issue":"5","key":"1858_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/0883073819895694","volume":"35","author":"G Lewis","year":"2020","unstructured":"Lewis G, Morrill AM, Conway-Allen SL, Kim B. Review of cerliponase alfa: recombinant human enzyme replacement therapy for late-infantile neuronal ceroid lipofuscinosis type 2. J Child Neurol. 2020;35(5):348\u201353.","journal-title":"J Child Neurol"},{"key":"1858_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejpn.2020.12.002","volume":"30","author":"B Estublier","year":"2020","unstructured":"Estublier B, Cano A, Hoebeke C, Pichard S, Scavarda D, Desguerre I, et al. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort. European journal of paediatric neurology\u202f: EJPN\u202f: official journal of the European Paediatric Neurology Society. 2020;30:17\u201321.","journal-title":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society"},{"issue":"9","key":"1858_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/ptj\/80.9.873","volume":"80","author":"DJ Russell","year":"2000","unstructured":"Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther. 2000;80(9):873\u201385.","journal-title":"Phys Ther"},{"issue":"10","key":"1858_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1469-8749.1998.tb12330.x","volume":"40","author":"D Russell","year":"1998","unstructured":"Russell D, Palisano R, Walter S, Rosenbaum P, Gemus M, Gowland C, et al. Evaluating motor function in children with Down syndrome: validity of the GMFM. Dev Med Child Neurol. 1998;40(10):693\u2013701.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1858_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nmd.2016.09.014","volume":"27","author":"T Sato","year":"2017","unstructured":"Sato T, Adachi M, Nakamura K, Zushi M, Goto K, Murakami T, et al. The gross motor function measure is valid for Fukuyama congenital muscular dystrophy. Neuromuscul Disord. 2017;27(1):45\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"1858_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.nmd.2006.03.005","volume":"16","author":"L Nelson","year":"2006","unstructured":"Nelson L, Owens H, Hynan LS, Iannaccone ST, Am SG. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord. 2006;16(6):374\u201380.","journal-title":"Neuromuscul Disord"},{"key":"1858_CR25","volume-title":"Gross motor function measure (GMFM-66 & GMFM-88) users manual","author":"DJ Russell","year":"2002","unstructured":"Russell DJ, Rosenbaum P, Wright M, Avery LM. Gross motor function measure (GMFM-66 & GMFM-88) users manual. United Kingdom: Mac Keith Press; 2002."},{"issue":"3","key":"1858_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00401-017-1739-1","volume":"134","author":"MS van der Knaap","year":"2017","unstructured":"van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134(3):351\u201382.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1858_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymgme.2018.05.003","volume":"124","author":"I Slavc","year":"2018","unstructured":"Slavc I, Cohen-Pfeffer JL, Gururangan S, Krauser J, Lim DA, Maldaun M, et al. Best practices for the use of intracerebroventricular drug delivery devices. Mol Genet Metab. 2018;124(3):184\u20138.","journal-title":"Mol Genet Metab"},{"key":"1858_CR28","doi-asserted-by":"crossref","unstructured":"Schwering C, Kammler G, Wibbeler E, Christner M, Knobloch JK, Nickel M, et al. Development of the \"Hamburg best practice guidelines for ICV-enzyme replacement therapy (ERT) in CLN2 disease\" based on 6 years treatment experience in 48 patients. J Child Neurol. 2021:883073821989154.","DOI":"10.1177\/0883073821989154"},{"issue":"1","key":"1858_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12887-015-0459-8","volume":"15","author":"LWME Beckers","year":"2015","unstructured":"Beckers LWME, Bastiaenen CHG. Application of the gross motor function measure-66 (GMFM-66) in Dutch clinical practice: a survey study. BMC Pediatr. 2015;15(1):146.","journal-title":"BMC Pediatr"},{"issue":"5","key":"1858_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0003-9993(02)04896-7","volume":"84","author":"LM Avery","year":"2003","unstructured":"Avery LM, Russell DJ, Raina PS, Walter SD, Rosenbaum PL. Rasch analysis of the Gross Motor Function Measure: validating the assumptions of the Rasch model to create an interval-level measure. Arch Phys Med Rehabil. 2003;84(5):697\u2013705.","journal-title":"Arch Phys Med Rehabil"},{"issue":"8","key":"1858_CR31","doi-asserted-by":"publisher","first-page":"e0132871","DOI":"10.1371\/journal.pone.0132871","volume":"10","author":"LJ Steenis","year":"2015","unstructured":"Steenis LJ, Verhoeven M, Hessen DJ, van Baar AL. Performance of Dutch children on the Bayley III: a comparison study of US and Dutch norms. PLoS ONE. 2015;10(8):e0132871.","journal-title":"PLoS ONE"},{"issue":"8","key":"1858_CR32","doi-asserted-by":"publisher","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","volume":"8","author":"A Orlin","year":"2013","unstructured":"Orlin A, Sondhi D, Witmer MT, Wessel MM, Mezey JG, Kaminsky SM, et al. Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS ONE. 2013;8(8):e73128.","journal-title":"PLoS ONE"},{"issue":"6","key":"1858_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1755-3768.1973.tb06044.x","volume":"51","author":"C Raitta","year":"1973","unstructured":"Raitta C, Santavuori P. Ophthalmological findings in infantile type of so-called neuronal ceroid lipofuscinosis. Acta Ophthalmol (Copenh). 1973;51(6):755\u201363.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"1858_CR34","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 26 Jan 2021."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01858-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01858-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01858-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T09:03:42Z","timestamp":1620983022000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01858-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1858"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01858-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Parents provided written informed consent for the use of the anonymized data of their children. As these data were obtained within a standardized clinical follow-up protocol formal approval from a medical ethical committee was not required as the study did not fall under the scope of the Dutch Medical Research Involving Human Subjects Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Parents provided written informed consent for the publication of the anonymized data of their children.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HHH has received a speaker fee, a participation fee for an advisory board and reimbursement for the ongoing participation in the 190\u2013504 registry study from BioMarin International Limited under an agreement between BioMarin International Limited and Erasmus MC University Medical Center. BioMarin International Limited was not involved at any stage of the study or during the preparation of the manuscript. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}